Aprea Therapeutics (Nasdaq: APRE) secures $30M and reports WEE1 trial response

Rhea-AI Filing Summary

Aprea Therapeutics, Inc. entered into a securities purchase agreement for an oversubscribed private placement expected to raise approximately $30 million in gross proceeds through pre-funded warrants and common stock warrants for up to about 37.2 million shares each. The warrants are priced at a purchase price of $0.808 per pre-funded warrant, with a common warrant exercise price of $0.683 per share. Aprea plans to use the upfront net proceeds for general corporate purposes and research and development and currently expects this funding to extend its cash runway into the first quarter of 2028. The company also reported a confirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer, along with additional stable disease cases, supporting early signs of anti-tumor activity.

Positive

• Strengthened liquidity and runway: Oversubscribed private placement expected to raise approximately $30 million in gross proceeds, with management indicating this should extend the company’s cash runway into the first quarter of 2028 to support ongoing R&D programs.
• Encouraging APR-1051 clinical signal: In the Phase 1 ACESOT-1051 trial, two partial responses have been observed in PPP2R1A-mutated endometrial cancers, including one confirmed with sustained tumor shrinkage and significant CA-125 reduction, alongside generally manageable safety.

Negative

• None.

Insights

Biotech equity analyst

$30M financing and early APR-1051 data strengthen Aprea’s clinical runway.

Aprea Therapeutics arranged an oversubscribed private placement expected to generate about $30 million in gross proceeds via pre-funded and common stock warrants. Management currently anticipates this capital will extend the company’s cash runway into the first quarter of 2028, supporting ongoing development activities.

The financing directly supports APR-1051, a WEE1 kinase inhibitor in the Phase 1 ACESOT-1051 trial. Among 24 patients treated from 10 mg to 220 mg once daily, two endometrial cancer patients with PPP2R1A mutations have achieved partial responses, one confirmed with a 50% initial and further 9.5% tumor reduction and CA-125 decline from 362 U/mL to 40.2 U/mL.

APR-1051 has been generally well tolerated, mainly Grade 1–2 nausea and fatigue, and dose escalation is continuing toward 300 mg once daily in Q2 2026. The company also plans to enroll more uterine serous carcinoma and Cyclin E-overexpressing, platinum-resistant ovarian cancer patients, aligning the new capital with biomarker-enriched development plans.

8-K Event Classification

5 items: 1.01, 3.02, 7.01, 8.01, 9.01

5 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Private placement gross proceeds: $30 million Pre-funded warrant shares: ≈37.2 million shares Common warrant shares: ≈37.2 million shares +5 more

8 metrics

Private placement gross proceeds $30 million Expected gross proceeds from oversubscribed private placement

Pre-funded warrant shares ≈37.2 million shares Maximum common stock underlying pre-funded warrants

Common warrant shares ≈37.2 million shares Maximum common stock underlying new common warrants

Common warrant exercise price $0.683 per share Exercise price of common stock purchase warrants

Pre-funded warrant exercise price $0.001 per share Nominal exercise price per pre-funded warrant share

Placement agent fee rate 7% Cash fee as a percentage of gross proceeds to placement agents

Runway guidance Into Q1 2028 Expected cash runway with proceeds, based on current plans

ACESOT-1051 patients treated 24 patients Number of patients treated in APR-1051 Phase 1 trial to date

Key Terms

Pre-Funded Warrants, Common Warrants, Registration Rights Agreement, Variable Rate Transaction, +2 more

6 terms

Pre-Funded Warrants financial

"pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to approximately 37.2 million shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Common Warrants financial

"common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “Warrant Shares”) at an exercise price of $0.683"

A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.

Registration Rights Agreement financial

"the Company and the Purchasers entered into a Registration Rights Agreement, dated March 30, 2026"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

Variable Rate Transaction financial

"entering into any agreement to effect the issuance any shares of Common Stock or any Common Stock equivalents involving a Variable Rate Transaction"

partial response (PR) medical

"announcing the confirmation of a partial response (PR) in its ongoing ACESOT-1051 trial evaluating APR-1051"

Partial response (PR) is a clinical result in which a measurable disease—such as tumor size or cancer markers—shrinks by a predefined, meaningful amount but does not disappear, as judged by standard rules used in drug trials. For investors, a PR is evidence the therapy has real biological effect and can de‑risk development, yet it still leaves questions about how long the benefit lasts and whether it will translate into a clear commercial or regulatory win, similar to early customer uptake that shows promise but not full market dominance.

WEE1 kinase inhibitor medical

"evaluating APR-1051, a potent and selective WEE1 kinase inhibitor"

A wee1 kinase inhibitor is a drug that blocks the Wee1 enzyme, a cellular “brake” that slows cell division to allow DNA repair. By releasing that brake, the inhibitor forces rapidly dividing, damaged cells—like many cancer cells—into lethal errors, which can shrink tumors. Investors care because clinical trial results, regulatory approvals, patent protection, and market demand for such targeted cancer therapies directly affect a company’s valuation and future revenue potential.

Understanding 8-K Material Events →

false 0001781983 0001781983 2026-03-30 2026-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

March 30, 2026

Date of Report (Date of earliest event reported)

Aprea Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39069		84-2246769
(State or other jurisdiction of incorporation)	(Commission File Number)		(IRS Employer Identification No.)
3805 Old Easton Road Doylestown, PA (Address of principal executive offices)		18902 (Zip Code)

Registrant's telephone number, including area code: (215) 948-4119

(Former name or former address, if changed since last report): Not applicable 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		APRE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry Into a Material Definitive Agreement.

On March 30, 2026, Aprea Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to approximately 37.2 million shares (the “Pre-Funded Warrant Shares”) of common stock, par value $0.001 per share of the Company (“Common Stock”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “Warrant Shares”) at an exercise price of $0.683 per share (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”). The closing of the private placement (the “Private Placement”) is expected to occur on March 31, 2026, subject to satisfaction of customary closing conditions (the “Closing Date”). The expected gross proceeds of the Private Placement are approximately $30 million, before deducting the placement agent fees and estimated offering expenses payable by the Company.

The Common Warrants will be exercisable immediately until December 31, 2029 (the “Termination Date”); provided, however, that, if the holder exercises all or any portion of the holder’s Pre-Funded Warrant, then, with respect to each such exercise of the holder’s Pre-Funded Warrant, the Termination Date of the Common Warrant with respect to such number of Warrant Shares as correspond to the number of shares of Common Stock issued upon such exercise of such Pre-Funded Warrant by the holder shall be the thirtieth (30^th) calendar day after the date upon which the holder exercises such Pre-Funded Warrant. If a resale registration statement covering the shares of Common Stock underlying the Common Warrants is not effective and available at the time of exercise, the Common Warrants may be exercised by means of a “cashless” exercise formula. The Common Warrants may not be exercised to the extent that immediately following such exercise, the holder would beneficially own greater than 4.99% (or, at the election of the holder, greater than 9.99%) of the Company’s outstanding Common Stock.

The unfunded exercise price of each Pre-Funded Warrant will be fixed at a nominal amount of $0.001 per underlying Pre-Funded Warrant Share (the “Pre-Funded Warrant Exercise Price”). The Pre-Funded Warrants will be exercisable from the date of issuance until exercised in full and may not be exercised to the extent that immediately following such exercise, the holder would beneficially own greater than 4.99% (or, at the election of the holder, greater than 9.99%) of the Company’s outstanding Common Stock. The Pre-Funded Warrants may be exercised by means of a “cashless” exercise formula at any time while outstanding.

The Warrants do not contain any Black Scholes cash payment obligations, any “price protection” anti-dilution protection or any “price reset” provisions pursuant to which the exercise price of the Warrants is subject to adjustment or reset at a future date or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market prices for the Common Stock, or upon any future issuance or sale by the Company of shares of its capital stock or securities exercisable or exchangeable for or convertible into shares of the Company’s capital stock at exercise or conversion prices below the exercise price of the warrants, other than standard pro rata adjustments for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction that would impact the Common Stock generally.

In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated March 30, 2026 (the “Registration Rights Agreement”), providing for the registration for resale of the Pre-Funded Warrant Shares and the shares of Common Stock underlying the Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) on or prior to the 30^th day after the Closing Date. The Company has agreed to use its reasonable best efforts to cause the Registration Statement to be declared effective as promptly as practicable, but in no event later than the earlier of (i) the fifth trading day following the date on which the Company is notified by the SEC that the Registration Statement will not be reviewed or is no longer subject to further review and comments and (ii) the 45^th calendar day following the date on which the Registration Statement is filed with the SEC (or, in the event of a “full review” by the SEC, the 60^th calendar day following the filing date), and to keep the Registration Statement continuously effective from the date on which the SEC declares the Registration Statement to be effective until such date that all Registrable Securities (as such term is defined in the Registration Rights Agreement) covered by the Registration Statement have been sold pursuant to a registration statement under the Securities Act or under Rule 144 as promulgated by the SEC under the Securities Act. The Company has granted the Purchasers customary indemnification rights in connection with the Registration Statement. The Purchasers have also granted the Company customary indemnification rights in connection with the Registration Statement.

The Purchase Agreement also prohibits the Company from: (a) for 90 days following the date the Registration Statement has been declared effective, issuing, entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of Common Stock or any Common Stock Equivalents (as defined in the Purchase Agreement) or filing any registration statement other than the Registration Statement contemplated by the Purchase Agreement, or (b) for 180 days following the date the Registration Statement has been declared effective the Company or its Subsidiaries (as defined in the Purchase Agreement) effecting or entering into any agreement to effect the issuance any shares of Common Stock or any Common Stock equivalents involving a Variable Rate Transaction (as defined in the Purchase Agreement), subject to customary exceptions, including, without limitation, (i) issuances contemplated by the Purchase Agreement, (ii) pursuant to employee benefit plans, or (iii) beginning on the 90th day following the date the Registration Statement has been declared effective, pursuant to the Company’s existing at-the-market offering sales agreement. The Company has agreed to pay the reasonable and documented fees and expenses of counsel to the Lead Investor (as defined in the Purchase Agreement) in an amount not to exceed $50,000 in the aggregate.

Additionally, each of the directors and executive officers of the Company, pursuant to lock-up agreements, agreed not to sell or transfer any of the Company securities which they hold, subject to certain exceptions, during the period beginning on the Closing Date through the close of trading on the date that is the ninetieth (90^th) day following the date the Registration Statement has been declared effective (each, a “Lock-Up Agreement”).

On March 30, 2026, and in connection with the Purchase Agreement, the Company entered into a customary placement agency agreement (the “Placement Agency Agreement”) with Oppenheimer & Co Inc. (“Oppenheimer”) and Maxim Group LLC (“Maxim” together with Oppenheimer, the “Placement Agents”). Pursuant to the Placement Agency Agreement, the Placement Agents are entitled to an aggregate cash fee of 7% of the gross cash proceeds paid by investors in the Private Placement (the “Placement Fee”). The Company has agreed to reimburse Oppenheimer for its reasonable expenses incurred in connection with the Private Placement in an aggregate amount not to exceed $50,000.

On March 30, 2026, in connection with the Private Placement, the Company entered into an Amendment to the Securities Purchase Agreement (the “Amendment”), effective as of March 26, 2026, with purchasers that purchased at least 50.1% in interest of the Shares (as defined in the January Purchase Agreement (as defined below)), to amend that certain Securities Purchase Agreement, dated January 28, 2026, by and among the Company and the purchasers party thereto (the “January Purchase Agreement”). Prior to the Amendment, the January Purchase Agreement prohibited the Company from (a) for a period of 30 days following the date the Registration Statement (as defined in the January Purchase Agreement) was declared effective, issuing, entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of Common Stock or any Common Stock Equivalents (each as defined in the January Purchase Agreement) or filing any registration statement other than the Registration Statement contemplated by the January Purchase Agreement, and (b) engaging in any Variable Rate Transaction (as defined in the January Purchase Agreement) for a period of 180 days following the date the Registration Statement contemplated by the January Purchase Agreement was declared effective. Pursuant to the Amendment, the January Purchase Agreement was amended to provide that the Company is prohibited (a) from the date of the January Purchase Agreement until March 26, 2026, from issuing, entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of Common Stock or any Common Stock Equivalents (each as defined in the January Purchase Agreement) or filing any registration statement other than the Registration Statement contemplated by the January Purchase Agreement, and (b) from effecting any Variable Rate Transaction (as defined in the January Purchase Agreement), until March 26, 2026, subject to customary exemptions.

The foregoing descriptions of the Pre-Funded Warrants, the Common Warrants, the Purchase Agreement, the Registration Rights Agreements, the Placement Agency Agreement, the Lock-Up Agreement and the Amendment are qualified in their entirety by reference to the full text of the forms of such documents, copies of which are attached hereto as Exhibits 4.1, 4.2, 10.1, 10.2, 10.3, 10.4 and 10.5 respectively, and each of which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.

Item 3.02 Unregistered Sales of Securities.

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Private Placement is incorporated herein by reference into this Item 3.02.

The Common Warrants, the Pre-Funded Warrants, and the shares of common stock underlying the Common Warrants and the Pre-Funded Warrants (collectively, the “Securities”) were, and will be, offered and sold in transactions exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder. Each Purchaser is an “accredited investor,” as defined in Regulation D, and is acquiring the Securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Accordingly, the Securities will not initially be registered under the Securities Act and the Securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.

Neither this Current Report on Form 8-K nor the exhibits attached hereto is an offer to sell or the solicitation of an offer to buy shares of common stock, notes, or any other securities of the Company.

Item 7.01 Regulation FD Disclosure.

On March 30, 2026, the Company issued a press release announcing the signing of Purchase Agreement with the Purchasers. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On March 30, 2026, the Company issued a press release announcing the confirmation of a partial response (PR) in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor. A copy of the press release is filed as Exhibit 99.2 hereto and incorporated herein by reference.

On March 30, 2026, the Company updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.3 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Title
4.1	Form of Pre-Funded Warrant
4.2	Form of Common Warrant
10.1*	Form of Securities Purchase Agreement
10.2	Form of Registration Rights Agreement
10.3	Form of Placement Agency Agreement
10.4	Form of Lock-Up Agreement
10.5	Form of Amendment to the Securities Purchase Agreement
99.1	Press Release of Aprea Therapeutics, Inc., dated as of March 30, 2026
99.2	Press Release of Aprea Therapeutics, Inc., dated as of March 30, 2026
99.3	Corporate Presentation (March 2026)
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

*Schedules and exhibits have been omitted from this exhibit pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aprea Therapeutics, Inc.
Dated: March 30, 2026	By:	/s/ Oren Gilad
	Name:	Oren Gilad, Ph.D.
	Title:	President and Chief Executive Officer

Exhibit 99.1

 

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

· Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors

DOYLESTOWN, PA, March 30, 2026 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the “Offering”).

The private placement was led by Soleus Capital with participation from other new investors, including Vestal Point Capital and Squadron Capital Management, existing investors and certain insiders of the Company.

In connection with the Offering the Company plans to sell (i) pre-funded warrants to purchase up to an aggregate of approximately 37.2 million shares of common stock (“Pre-Funded Warrants”), for a purchase price equal to $0.808, minus $0.001 per Pre-Funded Warrant, and (ii) warrants to purchase up to an aggregate of approximately 37.2 million shares of common stock. The warrants to be issued will have an exercise price of $0.683 per share, will be exercisable immediately upon issuance, and will expire on the earlier of (i) December 31, 2029, and (ii) 30 calendar days after the exercise of a holder’s Pre-Funded Warrant on a pro rata basis.

The gross proceeds to the Company from the Offering are estimated to be approximately $30 million before deducting the placement agent’s fees and other estimated Offering expenses. The Company intends to use the upfront net proceeds from the private placement for general corporate purposes and for research and development expenses. The Offering is expected to close on or about March 31, 2026, subject to the satisfaction of customary closing conditions.

In addition to the existing biomarker-enriched cohorts under evaluation in the ongoing ACESOT-1051 Phase 1 trial, Aprea plans to use commercially reasonable efforts to seek enrollment of at least 50 patients with uterine serous carcinoma (USC), as well as patients with Cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC) in order to further assess APR-1051 in selected patient populations with high unmet medical need. The Company currently anticipates completing dose escalation of the ACESOT-1051 trial in the second quarter of 2027 and currently expects that the proceeds from the Offering will be sufficient to extend its cash runway into the first quarter of 2028, in each case, based on the Company’s current business plans and assumptions.

Oppenheimer & Co. Inc. is acting as the lead placement agent for the private placement. Maxim Group LLC is acting as co-lead placement agent for the private placement.

The offer and sale of the foregoing securities are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities purchased in the private placement.

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

About Aprea

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, the risk that the proposed private placement and the transactions described herein may not be completed in a timely manner or at all, the failure to realize the anticipated benefits of the private placement and related transactions, market and other conditions, as well as other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

Investor Contact:

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Exhibit 99.2

 

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1
Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing
Phase 1 ACESOT-1051 Trial

· Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers

· Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor

· Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea’s development strategy of differentiated WEE1 inhibition with an improved therapeutic index

· A further update from the trial is expected in the second quarter of 2026

DOYLESTOWN, PA, March 30, 2026 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the confirmation of a partial response (PR) in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor.

The confirmed PR was observed in a patient with PPP2R1A-mutated endometrial cancer who is currently being treated at the 220 mg once daily dose level. Aprea announced on February 18, 2026 that, at their first imaging assessment, this patient achieved a 50% reduction in target lesion size (meeting RECIST criteria for partial response) as well as a reduction in CA-125 levels. This response was subsequently confirmed at the second image assessment, with an additional 9.5% reduction in target lesion size, and a reduction in CA-125 to 40.2U/ml (from 362 U/mL at baseline).

ACESOT-1051 is a biomarker focused Phase 1 trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of APR-1051 in patients with advanced solid tumors harboring cancer-associated genetic alterations. A total of 24 patients have been treated to date, at doses ranging from 10 mg to 220 mg once daily. Two patients have achieved partial responses, both with endometrial cancers harboring PPP2R1A mutations. One of these responses has been confirmed, as described above. Both patients remain on treatment.

Five other patients in ACESOT-1051 have achieved a best overall response of stable disease, including patients with HPV+ head and neck squamous cell carcinoma (HNSCC), colorectal and endometrial cancers with relevant genomic alternations. APR-1051 has been generally safe and well tolerated with the most common adverse events reported as Grade 1 or 2, primarily consisting of nausea and fatigue.

“The data emerging from the ACESOT-1051 trial continue to support the clinical potential of APR-1051, with confirmation of a partial response in the 220 mg cohort indicating evidence of sustained anti-tumor activity,” said Eugene Kennedy, MD, Chief Medical Advisor at Aprea. “APR-1051 appears to be generally well-tolerated with an encouraging therapeutic window and overall, these findings strengthen our confidence in the ability of this candidate to successfully target WEE1 in genetically defined cancers, where patients face significant unmet need.”

 

Dose escalation is ongoing, with plans to advance to Dose Level 9 (300 mg once daily) in the second quarter of 2026. In parallel, the company plans to enroll additional patients as specified in the protocol based on the understanding that their tumor types or specific mutations gives them an increased probability of responding to this class of potential therapeutics. This includes patients with uterine serous carcinoma (a subset of endometrial), colorectal and HPV+ tumors. For more information on ACESOT-1051, refer to ClinicalTrials.gov NCT06260514.

About Aprea

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.

Investor Contact:

Mike Moyer

LifeSci Advisors

mmoyer@lifesciadvisors.com

Exhibit 99.3

1 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers March 2026

2 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward-Looking Statements Certain information contained in this presentation includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and our ability to predict clinical outcomes based on such preclinical and early clinical result, and our ability to continue as a going concern, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this presentation. We undertake no obligation to update such forward-looking statements for any reason, except as required by law. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This presentation may not be reproduced, forwarded to any person or published, in whole or in part. Private placements are speculative, illiquid, carry a high degree of risk and securities issued in a private placement should only be purchased by persons who can afford the loss of their entire investment.

3 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE) One Critical Pathway - Multiple Targets DNA Damage Response (DDR) 1. Ngoi N, et al. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cancer. (2021); 7(10):930-957 Precision Medicine Synthetic Lethality Aprea DYRK1 Target Trends in Cancer 1 Positioned at the Forefront of Synthetic Lethality and Precision Medicine Transition from broad, toxic chemotherapy to potentially safer, precision-guided targeted therapies Targeted Oncology Develop highly selective cancer therapies that exploit tumor-specific mutations to maximize cancer cell killing while sparing healthy tissue Precision-Driven Development All programs are designed to address significant unmet medical needs across genetically defined cancer populations Pipeline with Clinical Momentum Single agent activity demonstrated in ongoing Phase 1 trial Early Clinical Proof-of-Concept

4 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust DDR Development Pipeline Milestones 2024-2026 Accomplished and anticipated clinical milestones 2024 2025 2026 H1 H2 H1 H2 H1 H2 ATR ATRN-119 WEE1 APR-1051 RP2D for QD dosing ACESOT-1051: Phase 1 – Monotherapy Dose Escalation Enrolled First Patient Complete Dose Escalation IND Cleared ABOYA-119: Phase 1 Monotherapy Dose Escalation: QD* BOIN Design Initiate BID Regimen Optimization ABOYA-119: Phase 1 Monotherapy Dose Escalation: BID* * We have started an orderly wind-down of certain clinical trial site activities associated with the monotherapy arms as we explore ATTN-119 in potential combination approaches Safety & Efficacy Data Safety & Efficacy Data Combinations Safety & Efficacy Data Backfill

5 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Strong Drug Development and Commercial Expertise Experienced team in synthetic lethality and targeted therapy Management Board of Directors Richard Peters, M.D., Ph.D. Chairman of the Board Oren Gilad, Ph.D. President and CEO Jean-Pierre Bizzari, M.D. Director Marc Duey Director Michael Grissinger Director Gabriela Gruia, M.D. Director John Henneman Director Rifat Pamukcu, M.D. Director Bernd R. Seizinger, M.D., Ph.D. Director Oren Gilad, Ph.D. President and CEO John P. Hamill Sr. Vice President and CFO Eugene Kennedy, MD Chief Medical Advisor Ze’ev Weiss, CPA, B.Sc. Chief Business Advisor Mike Carleton, Ph.D. Translational Medicine Advisor Brian Wiley SVP, Corporate Strategy

6 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 6 WEE1 Inhibitor: APR-1051 ACESOT-1051: Clinical Proof-Of-Concept

7 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Next–Generation WEE1 Inhibitor Expanding the Therapeutic Index 1. Zentalis Corporate Presentation, January 2026 2. Debio 0123-101, A Phase 1 Trial of Debio 0123 In Combination With Carboplatin In Advanced Solid Tumors: Safety, Pharmacokinetic, And Preliminary Antitumor Activity Data, Poster ASCO 2023 3. Results of A Phase 1, Dose-Finding Study of Debio 0123 As Monotherapy In Adult Patients With Advanced Solid Tumors —Safety, Pharmacokinetic, And Preliminary Antitumor Activity Data, Poster ASCO 2024 Targeting the clinically validated WEE1 pathway with an engineered profile aimed at widening the therapeutic window and improving tolerability versus earlier inhibitors Program Clinical Limitation Strategic Outcome What It Signals Adavosertib (AstraZeneca) Hematologic & GI toxicity limited dose intensity Terminated further clinical development Returned by AstraZeneca to Merck & Co. Biology works, narrow therapeutic window Azenosertib (Zentalis) Continuous dosing not tolerated1 Ongoing dosing and schedule optimization Biology works, therapeutic window still being defined Debio 0123 (Debiopharm) QT prolongation liability at high doses2 Limited single-agent activity – no clinical responses at doses up to and including at MTD3 Cardiac safety restricts exposure APR-1051 (Aprea Therapeutics) Early signals of tumor reduction without class-limiting tox to date Dose escalation progressing Potentially widened therapeutic window No head-to-head studies have been conducted. Trial information is based on publicly available data and should be interpreted cautiously.

8 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved ACESOT-1051: Phase 1 Study Design * Higher doses permitted if indicated Multi-center, open-label Phase 1 single-agent dose escalation and dose selection optimization Part 1 Dose escalation up to 50 patients RP2D Oral single-agent APR-1051 will be administered once-daily for 28-day cycles Objectives Primary: Safety, DLT, MTD/MAD, RP2D Secondary: Pharmacokinetics, Antitumor activity (RECIST/PCWG3) Exploratory: Pharmacodynamics = cleared Accelerated titration; 1-6 patients per dose level BOIN design; 3-12 patients per dose level Part 2 Dose selection optimization Up to 80 patients Selected dose 2 Selected dose 1 1:1 randomization R Dose level 1 10 mg Dose level 2 20 mg Dose level 3 30 mg Dose level 4 50 mg Dose level 5 70 mg Dose level 6 100 mg Dose level 7 150 mg Dose level 8 220 mg Dose level 9 300mg* Confirmed PR Observed First uPR Observed Select 2 dose levels Eligible patients ≥ 18 yo with advanced solid tumor harboring cancer-associated gene alterations o CCNE1,CCNE2, FBXW7 or PPP2R1A o USC regardless biomarker status o HPV+ oropharyngeal squamous cell carcinoma, cervical, vaginal, or vulvar carcinoma o KRAS-GLY12/GLY13 & TP53 colorectal cancer = currently enrolling Backfill Backfill Backfill

9 © 2026 Aprea Therapeutics, Inc. All Rights Reserved 50 36 44 21 22 42 44 55 56 43 49 223 36 56 112 178 28 111 85 12 58 63 7 0 50 100 150 200 250 02-001 01-001 01-002 01-003 01-004 02-002 03-002 03-003 03-004 02-003 03-005 01-005 03-007 01-006 03-008 03-006 03-010 01-010 01-008 03-011 03-012 01-011 01-012 220 mg 150 mg 100 mg 70 mg 50 mg 30 mg 20 mg 10 mg Days on treatment Study patient APR-1051 once-daily dose Not all data source verified ✼ Data cutoff: February 18, 2026 ✼ Progressive disease (PD) Stable disease (SD) Consent withdrawn Treatment continues Physician decision Unrelated death Partial response* (PR) APR-1051 Summary of Duration of Treatment (n=23) * Unconfirmed ✼ ✼ ✼ ✼ ✼ ✼ ✼ ✼ ✼ ✼ ✼ ✼ ✼ Enrollment status

10 © 2026 Aprea Therapeutics, Inc. All Rights Reserved MedDRA Preferred Term APR-1051 All dose levels (N=23) Treatment-related AEsa All Grades n (%) Grade ≥ 3b n (%) Nausea 7 (30.4) 0 (0) Fatigue 4 (17.4) 0 (0) Vomiting 2 (8.7) 0 (0) Alanine aminotransferase increased 1 (4.3) 1 (4.3)c Aspartate aminotransferase increase 1 (4.3) 1 (4.3)c Anemia 1 (4.3) 0 (0) Blood bilirubin increased 1 (4.3) 0 (0) Constipation 1 (4.3) 0 (0) Dehydration 1 (4.3) 0 (0) Dysgeusia 1 (4.3) 0 (0) Dyspepsia 1 (4.3) 0 (0) Gastroesophageal reflux disease 1 (4.3) 0 (0) Hypokalemia 1 (4.3) 0 (0) Lymphocyte count decreased 1 (4.3) 1 (4.3) Treatment-related AEs in Patients Treated with APR-1051 (N=23) a A patient may have more than one AE and/or have the same AE more than once b Grade 3 unless otherwise indicated c Increased alanine aminotransferase and aspartate aminotransferase occurred in the same patient and was considered one DLT event Not all data source verified Data cutoff: February 18, 2026

11 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Confirmed Partial Response in Patient 01-011 • 220 mg QD (On Treatment) • Demographics: 63-year-old Black Female Site: MD Anderson Cancer Center Diagnosis: Uterine carcinosarcoma (form of endometrial) Key Mutations: PPP2R1A • Treatment History (4 prior lines) • Line 1: Carboplatin + Paclitaxel → 126 days, PD (Apr-Sep 2024) • Line 2: Doxorubicin → 56 days, PD (Sep-Nov 2024) • Line 3: Topotecan → 70 days, PD (Dec 2024-Feb 2025) • Line 4: Pembrolizumab + Lenvatinib → 5months, PD (May 2025-Oct 2025) • APR-1051 Response • C1D1: Dec 18, 2025 • Current Status: Mar 10, 2026 On treatment 83 days (C4D1) • Best Response: Confirmed PR (additional -9.5% reduction from C3D1) Mar 10, 2026 PR (-50%) at first assessment Feb 10, 2026 • Tumor marker: CA-125 reduction from BL 362.4 U/mL to C3D1 46.8 U/mL (87% decrease); 40.2 U/mL Mar 11, 2026 • Adverse Events: C1D22. Grade 1 rash. Gr1 thrombocytopenia at C1D15 possible relation to IP. Intermittent Nausea Gr1 probably related. Amylase Increase Gr1 unlikely related. No DLT.

12 © 2026 Aprea Therapeutics, Inc. All Rights Reserved Partial Response in Patient 01-010 • 150 mg QD (On treatment) • Demographics: 68-year-old White Female Site: MD Anderson Cancer Center Diagnosis: Uterine Serous Carcinoma (Stage IV, M1) Key Mutations: PPP2R1A • Treatment History (4 prior lines) • Line 1: Paclitaxel + Carboplatin → 105 days, CR (Aug 2023 - Nov 2023) • Line 2: Docetaxel + Carboplatin → 134 days, PR (Sep 2024 - Feb 2025) • Line 3: Letrozole → 79 days, PD (Apr 2025 - Jul 2025) • Line 4: AKT1 E17K Allosteric Inhibitor → 55 days, PD (Aug 2025 - Oct 2025) • APR-1051 Response • C1D1: Oct 31, 2025 • Current Status: Mar 19, 2026 On treatment with progression after treatment interruption unrelated to study drug • Best Response: uPR (-50%) at first assessment Dec 21, 2025 • Duration: 131 days (as of Mar10, 2026) • Tumor marker: CA-125 reduction from 732 to 69.5 U/mL (>90% decrease) on Dec 22, 25 - Increased during treatment interruption to 277.5 U/mL on Jan 21, 26; most recent Mar 04, 26: 291.6 U/mL • Last assessment: 01Mar26 - PD (+52.9% from nadir but still -23.5% from baseline), no new lesion; continuing on treatment for clinical benefit • Grade ≥3 AEs: Elevated Creatinine (G3), Hypercalcemia (G4), Elevated Lipase/Amylase (G4) all unrelated to study drug • Pancreatitis (G3), not related to APR-1051, pt hospitalized, APR-1051 interrupted. • Anemia (G3) w/ HgB 7.7; referred to ED & admitted 22Jan26 for melena; not related to APR-1051, pt hospitalized. (Jan 3-Feb 1), restarted at 150mg on Feb02, 26.

13 © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051 (ACESOT-1051): Update March 10th, 2026 • Seven dose levels cleared: 10 mg, 20 mg, 30 mg, 50 mg, 70 mg, 100mg, 150 mg QD • Efficacy update – Two partial responses (PRs) observed, one confirmed thus far • Patient 01-011 (220 mg): Confirmed PR (additional -9.5%) Mar 10, 2026 Unconfirmed PR with ~50% reduction at first assessment Feb 10, 2026; in uterine carcinosarcoma (UCS), Mutation: PPP2R1A • CA-125 reduction from BL 362.4 U/mL to C3D1 46.8 U/mL (87% decrease) to 40.2U/mL March 11, 2026 • Patient 01-010 (150 mg): Unconfirmed PR with -50% tumor shrinkage in uterine serous carcinoma (USC), Mutation: PPP2R1A • Patient off study due to AE not related to study drug for 30 days, restarted study drug at 150mg Feb 02, 2026, follow up scan after 30 days back on drug show +52.9% progression from nadir but still -23.5% from baseline • CA-125 biomarker: 90% reduction initially: 732 baseline →69.5 Dec 22, 2025(nadir); 277.5 Jan 21, 2026 (while off treatment); essentially stable once back on treatment 291.6 U/mL Mar 04, 2026 • Patient to remain on study drug at 150mg and rescan • Dose 8 (220 mg) cohort enrolling: • Four patients enrolled (01-011, 03-011, 03-012, 01-012), C1D1 from Dec 17, 2025 to Feb 12, 2026 • 03-011 deceased (G5 cardiac arrest [ventricular fibrillation], Day 12, unlikely related), HPV+, replaced • No DLTs for 01-011 and 03-012 • 01-012 experienced hospitalization for G3 colon obstruction, deemed unrelate, study treatment held resulting in <75% of cycle 1 doses administered, to be replaced as concerns DLT clearance; to remain on study treatment if clinician believes there is potential benefit • Next planned dose: 300 mg; no dose reductions for any patients in 220mg and 150mg cohorts as of March 10, 2026. • Patient status changes • 03-006 (100 mg): 86 year old withdrew consent / opted to stop study treatment after 178 days – achieved SD with -14.8% shrinkage, mutation FBXW7 • 03-012 (220 mg): Disease progression after 58 days, mutation KRAS G12 + TP53 • Safety note – Patient 01-012 (220 mg) • Grade ≥3 AEs: colonic obstruction, unrelated to study drug • Restart of study drug at 220mg planned; mutation PPP2R1A + CCNE1

14 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Disease Control Observed in Early Patient Outcomes APR-1051 shows single agent activity in cancer with mutated FBXW7 Clinical Data 100 mg Cohort Patient: 86-year-old Asian Female Diagnosis: Rectal Cancer Key Mutations: FBXW7 (Drives Cyclin E accumulation and overexpression) Treatment History: 5 prior lines - heavily pretreated • Line 1: Capecitabine/oxaliplatin → 191 days, PD • Line 2: Capecitabine/oxaliplatin/bevacizumab → 45 days, PD • Line 3: FOLFIRI + bevacizumab → 43 days, PD • Line 4: Local XRT (lung mets) → 12 days, not evaluable • Line 5: Tretinoin/bevacizumab/Tecentriq (ATRT trial) → 50 days, PD APR-1051 Activity: • Current Status: Consent withdrawn after 178 days • Best Response: SD at third scan (-15% tumor response) Notes: Durable SD maintained 181 days in a heavily pretreated 86-year-old patient; well tolerated with minimal toxicity. FBXW7 mutation may be relevant to response Stable disease maintained for 178 days in patient with FBXW7 mutation (100 mg QD) (Consent withdrawn)

15 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Clinical Data 70 mg Cohort Disease Control Observed in Early Patient Outcomes Patient: 62-year-old White Male Diagnosis: HPV+ Oropharyngeal Squamous Cell Carcinoma (base of tongue) Key Mutations: P16+ Treatment History: 3 prior lines • Line 1: Concomitant cisplatin/XRT → 49 days, PD • Line 2: Pembrolizumab→ 84 days, PD • Line 3: Paclitaxel/carboplatin → 184 days, PD APR-1051 Activity • Current Status: PD after 223 days of SD treatment • Best Response: SD at first scan (-5% tumor response) Notes: Stable disease maintained for 223 days. APR-1051 shows single agent activity in HPV+ head and neck cancer Stable disease maintained for 223 days in patient 01-005 HPV+ head and neck cancer (70 mg QD) (PD)

16 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved A Biomarker Defined Path to Registration Data are preliminary from an ongoing dose-escalation study. Responses and stable disease require confirmation in additional patients, and may change as follow-up matures. Safety and efficacy outcomes may vary by dose, schedule, and patient characteristics. Early responses across cohorts in PPP2R1A-mutated endometrial cancer, with additional disease control signals across broader genomically defined tumors Objective Responses PPP2R1A-mutated endometrial cancer • Confirmed Partial Response at 220 mg • Partial Response at 150 mg Disease Control FBXW7-mutated CRC • Stable disease at 100 mg HPV+ Head and Neck • Stable disease at 70 mg Safety • Well tolerated to date • Potential wide therapeutic window • Responses across dose levels support a biomarker enriched expansion path • Activity beyond endometrial cancer supports additional biomarker-defined cohorts Clinical Activity by Biomarker and Dose Path to Registrational Cohort 1 Expand PPP2R1A-mutated cohort Add additional cohorts • FBXW7-mutated CRC • HPV+ cancers 2 Confirm durability, consistency of response and safety 3

17 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved HPV+ Cancer – Collaboration with MD Anderson Ovarian Cancer* UMSCC47 tumor cells OVCAR3 tumor xenograft Tumor Volume (mm3 ) Vehicle Aprea ATRi 30 mg/kg QD Aprea WEE1i 30 mg/kg QD Combination – half dose, 15mg/kg each Days Post Treatment Tumor Volume (mm3 ) Days since start of xenograft mEER tumor cells Tumor Volume (mm3 ) Days since start of xenograft APR-1051 Demonstrated Preclinical Activity in Combination with Chemo, IO and ATRi Across Multiple Cancer Models * Data on file. Start of treatment 0 10 20 30 0 20 0 0 0 100 ntreated AP 1051 Cis atin C m Start of treatment ** P<0.0001 * P=0.0067 ** ** * Chemotherapy Immuno-oncology DDR combination APR-1051 demonstrates synergistic potential preclinically with standard oncology agents

18 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Summary APR-1051 aims to be the first WEE1 inhibitor to translate validated biology into a scalable commercial asset 1 Clinically validated target • WEE1 inhibition has shown promising activity in genomically defined tumors APR-1051 opportunity • Early clinical proof-of-concept at 150 mg and 220 mg dose levels • Potentially favorable safety profile at active dose levels • Enrollment continues, additional clinical data expected over the next 3-6 months • Clinical team strengthened to drive next phase of development • Capital in place to achieve meaningful inflection points • Valuation lags fundamentals, creating an asymmetric opportunity Competitor programs constrained by low therapeutic index • Dose intensity and duration limited by hematologic, GI or cardiac toxicity 2 3

19 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 19 APR-1051: Potentially Differentiated WEE1 Inhibitor Pre-Clinical

20 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Potentially Best-in-Class WEE1 Inhibitor Structurally differentiated: high potency, limited off-target inhibition design compared to other molecules AstraZeneca Adavosertib (AZD-1775) Zentalis Azenosertib (ZN-c3) Aprea APR-1051 Undisclosed APR-1051 is based on a different molecular structure from AZD-1775 and ZN-c3 No head-to-head clinical studies have been conducted.

21 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR-1051: Potentially Best-in-Class WEE1 Inhibitor Potent inhibitor of WEE1 Does not substantially inhibit structurally and functionally related PLK1, PLK2 or PLK3 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK1 IC50 Determination Log10 [conc] (M) % Activity ZN-c3 APR-1051 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK2 IC50 Determination Log10 [conc] (M) % Activity ZN-c3 APR-1051 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK3 IC50 Determination Log10 [conc] (M) % Activity ZN-c3 APR-1051 ZN-c3 = 92.1 nM APR-1051 = 15,900 nM PLK1 Inhibition IC50 >150-fold difference ZN-c3 = 32.0 nM APR-1051 = 1,800 nM PLK2 Inhibition IC50 >50-fold difference ZN-c3 = 52.2 nM APR-1051 = 31,600 nM PLK3 Inhibition IC50 >600-fold difference Important difference in off-target inhibition between APR-1051 and ZN-c3 On 1 -target WEE1 potency1 ZN-c3 = 2.9 nM APR-1051 = 1.6 nM WEE1 Inhibition IC50 similar to ZN-c3 125 100 75 50 25 0 10 9 8 7 6 5 APR 1051 c3 WEE1 IC50 Determination % Activity Log10 [conc] (M) 1 AACR-NCI-EORTC Meeting, Poster B323, 2024 Data from exploratory in-vitro studies APR-1051 specificity for WEE1 opens potential for greater therapeutic window

22 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved PLK1 Inhibition Counteracts Effect of WEE1 Inhibitors1 Minimal PLK1 co-inhibition enhances therapeutic window for APR-1051 37 nM 111 nM 333 nM 1 µM 37 nM 111 nM 333 nM 1 µM Phos-H2AX Control (MCM3) NT Phos-CDK1 APR-1051 75 nM GSK-PLKi Control (MCM3) 37 nM 111 nM 333 nM 1 µM 37 nM 111 nM 333 nM NT 1 µM Phos-H2AX 400 nM BI-PLKi APR-1051 Phos-CDK1 PLK inhibitor, BI-2536, interferes with the effects of APR-1051 in OVCAR-3 cells 1 AACR-NCI-EORTC Meeting, Poster B323, 2024 Data from exploratory in-vitro studies Evidence of DNA damage allowed by WEE1 inhibition. PLK1 reduces functional potency of WEE1 inhibition PLK inhibitor, GSK-461364, interferes with the effects of APR-1051 in OVCAR-3 cells Inhibition of PLK1 reduces efficacy of APR-1051 inhibition. Results in requiring higher doses of WEE1 inhibitors and introduces PLK1 related toxicity

23 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Studies Show PLK1 Suppression is Associated with Sepsis-Induced Loss of Intestinal Barrier Function 1 PLK1 protects against sepsis-induced intestinal barrier dysfunction, Cao et al, Scientific Reports (2018). 2 PLK1 protects intestinal barrier function in sepsis: A translational research, Cao et al, Cytokine (2023). 3 PLK1 protects intestinal barrier function in sepsis: A translational research, Cao et al, Molecular Medicine (2022). 4 LncRNA DANCR improves the dysfunction of the intestinal barrier and alleviates epithelial injury by targeting the miR‐1306‐5p/PLK1 axis in sepsis, Wang et al., Cell Biology International (2021).

24 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 24 Intellectual Property Portfolio Financial Summary & Capitalization Investment Highlights

25 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust Global Intellectual Property Protection Family 1: Ataxia Telangiectasia and Rad3-Related (ATR) Protein Kinase Inhibitors • Macrocyclic inhibitors of ATR & methods of using them to treat various cancers, filed on Oct. 13th, 2015 • Patents granted in AU, BR, CA, CN, EP, IL, IN, JP, KR, MX, HK. • 1.1: Issued on May 30, 2017 as U.S. Patent 9,663,535 • 1.2: Issued on May 29, 2018 as U.S. Patent 9,981,989 • 1.3: Issued on Feb. 5, 2019 as U.S. Patent 10,196,405 Family 2: ATR Inhibitors and Methods of Use • Carboxylic acid-containing macrocyclic ATR inhibitors, and prodrugs; methods of using these inhibitors to treat various cancers; filed on Apr. 12th, 2017 • Issued on May 28th , 2019 as U.S. Patent 10,301,324 Family 3: ATR Inhibitor Pharmaceutical Composition and Methods • International application filed on Apr. 14th, 2023 • Pharmaceutical formulation and composition of our lead ATR inhibitor in the clinic • Patent granted in JP; Applications pending US, AU, BR, CA, CN, EA, EP, HK, IL, IN, KR, MX, NZ, PH, SG, ZA Family 4: WEE1 Inhibitor Pharmaceutical Compositions and Methods • International Application filed on Jun. 3rd, 2022 • Composition of our lead WEE1 inhibitor compounds • Patent granted in AU; Applications pending in US, AU, BR, CA, CN, EP, HK, IL, IN, JP, KR, MX, ZA Family 5: Methods of Treating Cancer • International application filed on Sept. 19, 2025 • Clinical methods of treating advanced solid cancer tumors using lead ATR inhibitor Family 6: Macrocyclic Undisclosed DDR target Inhibitors and Methods of their Preparation and Use • International application filed on Jan. 22, 2026 • U.S. Provisional Applications filed on Jun. 6, 2025, and Sep. 19, 2025

26 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Securities Common Equivalents as of March 9, 2026 Preferred Stock (as converted) 15,596 Common Stock (1) 11,452,452 Warrants (2) 16,212,687 Options 840,121 Restricted Stock Units 25,176 Fully Diluted Equivalents 28,546,032 Aprea Therapeutics (NASDAQ: APRE) Financial Summary and Capitalization 1. 400,000,000 common shares authorized 2. Total warrants include pre-funded, Tranche A, Tranche B and Purchase Cash and Equivalents of ~$14.6M as of December 31, 2025 $5.6M in gross proceeds raised in private placement Jan 30, 2026

27 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Expected cash runway into Q1 2027 • Achieve near term inflection points and catalysts • Evaluate optimal strategic partnerships Near term catalysts • APR-1051: Q1 2026 Safety/efficacy data ✓ Q3 2026 Complete dose escalation • ATRN-119: October 2025 RP2D ✓ H2 2026 Potential collaborations on combinations Highly potent and selective design, potential best in class inhibitors, de-risked programs • Diversified portfolio including WEE1 (APR-1051) and ATR (ATRN-119) inhibitors • Early evidence of clinical activity including PRs (one confirmed) with APR-1051 • Single agent and combination potential therapies Technology developed by pioneers in synthetic lethality • Management with strong drug development and commercial expertise Investment Highlights

28 | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE)

FAQ

What did Aprea Therapeutics (APRE) announce about its new financing?

Aprea Therapeutics announced an oversubscribed private placement expected to generate about $30 million in gross proceeds. The deal uses pre-funded warrants and common stock warrants, and the company plans to apply net proceeds to general corporate purposes and research and development activities.

How many Aprea Therapeutics shares are covered by the new warrants?

The financing includes pre-funded warrants to purchase up to approximately 37.2 million shares of common stock and additional common stock warrants for up to approximately 37.2 million shares. These securities give investors the right to acquire shares at preset exercise prices over defined periods.

What are the key pricing terms of Aprea’s new warrants?

Each pre-funded warrant has a purchase price of $0.808 less a nominal $0.001 exercise price per share. The common stock warrants carry an exercise price of $0.683 per share and are exercisable immediately, generally through December 31, 2029, subject to specific shortening mechanics.

How long does Aprea expect its cash runway to last after this financing?

Aprea currently expects that net proceeds from the approximately $30 million private placement will extend its cash runway into the first quarter of 2028. This guidance is based on the company’s present business plans, development priorities, and underlying operating assumptions.

What new clinical data did Aprea report for WEE1 inhibitor APR-1051?

Aprea reported a confirmed partial response in a PPP2R1A-mutated endometrial cancer patient in its Phase 1 ACESOT-1051 trial. The patient saw a 50% initial tumor reduction, an additional 9.5% decrease, and CA-125 drop from 362 U/mL to 40.2 U/mL, with ongoing treatment.

How many patients have been treated so far in the ACESOT-1051 trial?

The ACESOT-1051 Phase 1 study has treated 24 patients with advanced solid tumors at doses between 10 mg and 220 mg once daily. Two have achieved partial responses and five others have had stable disease, with dose escalation and biomarker-enriched enrollment continuing.

What future clinical milestones did Aprea outline for APR-1051?

Aprea plans to escalate APR-1051 dosing to 300 mg once daily (Dose Level 9) in Q2 2026 and enroll more patients with uterine serous carcinoma and Cyclin E-overexpressing, platinum-resistant ovarian cancer. The company anticipates completing dose escalation in the ACESOT-1051 trial in the second quarter of 2027.

Filing Exhibits & Attachments

13 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 13.0 KB
• EX-99.2 EXHIBIT 99.2 19.6 KB
• EX-99.3 EXHIBIT 99.3 52.8 KB

Agreements & Contracts

• EX-10.1 EXHIBIT 10.1 213.5 KB
• EX-10.2 EXHIBIT 10.2 146.8 KB
• EX-10.3 EXHIBIT 10.3 71.2 KB
• EX-10.4 EXHIBIT 10.4 29.2 KB
• EX-10.5 EXHIBIT 10.5 18.1 KB

Other Documents

• EX-4.1 EXHIBIT 4.1 94.8 KB
• EX-4.2 EXHIBIT 4.2 96.7 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB